PRINCETON, NJ, December 18, 2023 – WCG, the global leader in providing solutions that improve and accelerate clinical research, is pleased to announce the appointment of three industry leaders to its board of directors. The strategic additions of Ken Getz, Bob Hugin, and Dr. Amrit Ray bring a wealth of experience and expertise to guide the continued growth and value creation at WCG.
Ken Getz is the executive director of the Tufts Center for the Study of Drug Development and a renowned industry thought leader. He is an expert in drug research and development, clinical trial management practices, patient engagement, and industry trends. Getz also serves as a research professor at Tufts University School of Medicine, Public Health, and Community Medicine and is the founder of the clinical research non-profit, CISCRP.
Bob Hugin is the former CEO and chairman of Celgene and former chairman of the board of The Pharmaceuticals Research and Manufacturers of America (PhRMA). With a notable background as a director of various corporations, including Chubb Limited and Biohaven Pharmaceuticals Inc., Hugin brings invaluable insights into corporate leadership, strategy, and governance.
Amrit Ray, MD, is the former global president and head of R&D at Pfizer Upjohn. As a distinguished physician researcher, Dr. Ray enhances the board with his extensive biopharmaceuticals experience across research, phases I – IV development, regulatory, safety, and medical affairs on a global scale. Along with his board director experience at companies such as Fortrea, Ultragenyx, and Press Ganey, Dr. Ray is a trustee at The Hastings Center for bioethics and serves on the steering group of the Good Clinical Trials Collaborative, reflecting his commitment to patient advocacy and advancing global healthcare.
WCG’s Chief Executive Officer, Sam Srivastava, expressed enthusiasm about the new appointments, stating, “We are thrilled to welcome Ken, Bob, and Amrit to our already talented board of directors. Their leadership, experience, and market presence will be instrumental in our continued growth and success as we create meaningful impact for our clients, partners, and the industry, helping to overcome barriers to effectively advance research that can impact and save lives.”
These additions to the board of directors will further strengthen WCG’s position as a thought leader and trusted partner in clinical research. This further underscores WCG’s relentless commitment to advancing clinical research and dedication to innovation and excellence.
For media inquiries, please contact:
Carmin Gade, PhD
Chief Marketing Officer, WCG
484.351.9959
[email protected]